To analyze the relationship between CTNNA2 mutation and prognosis in NSCLC and LUAD patients without immunotherapy, we used the MSKCC cohort and found that CTNNA2 mutation had no effect on progression-free survival (PFS) (Supplementary Figures S4A,B). Here, CTNNA2 is linked to non-small cell lung carcinoma.